These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 12948434)

  • 1. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.
    Lakkis J; Lu WX; Weir MR
    Curr Hypertens Rep; 2003 Oct; 5(5):408-17. PubMed ID: 12948434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.
    Brennan BJ; Martin NE
    J Am Pharm Assoc (2003); 2004; 44(5):604-10; quiz 610-1. PubMed ID: 15496047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: a selective aldosterone receptor antagonist (SARA).
    Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
    Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid receptor antagonists and hypertension: is there a rationale?
    Gumieniak O; Williams GH
    Curr Hypertens Rep; 2004 Aug; 6(4):279-87. PubMed ID: 15257862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
    Salam AM
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1423-7. PubMed ID: 12882627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone, a new selective aldosterone blocker.
    McMahon EG
    Curr Pharm Des; 2003; 9(13):1065-75. PubMed ID: 12678858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states.
    Brewster UC; Setaro JF; Perazella MA
    Am J Med Sci; 2003 Jul; 326(1):15-24. PubMed ID: 12861121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone as a mediator in cardiovascular injury.
    Stier CT; Chander PN; Rocha R
    Cardiol Rev; 2002; 10(2):97-107. PubMed ID: 11895576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone receptor antagonists for hypertension: what do they offer?
    Liew D; Krum H
    Drugs; 2003; 63(19):1963-72. PubMed ID: 12962513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
    Davis KL; Nappi JM
    Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
    Struthers AD; MacDonald TM
    Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders.
    Perazella MA; Setaro JF
    J Nucl Cardiol; 2003; 10(2):184-96. PubMed ID: 12673184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.